摘要
目的布地奈德联合复方异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭患者疗效及对血气指标、血浆脑利钠肽(BNP)水平的影响。方法选择医院2015年1月至2018年1月就诊COPD合并Ⅱ型呼吸衰竭患者120例,按随机数字表法分为两组,各60例。两组患者均进行常规治疗,对照组在此基础上使用雾化吸入布地奈德,2 mg/次,2次/d,治疗7 d;观察组在对照组基础上给予雾化吸入复方异丙托溴氨1.25 mL/次,2次/d,治疗7 d。统计两组患者疗效,检测两组患者治疗前后血浆BNP水平及左室射血分数(LVEF)检测两组患者治疗前后肺功能,统计两组患者治疗前后血气水平,统计两组患者不良反应发生率。结果治疗后,观察组症状消失时间比对照组更短(P<0.05);治疗后,观察组心功能比对照组提升更明显,血浆BNP比对照组降低更明显(P<0.05);治疗后,观察组肺功能比对照组改善更明显;治疗后,观察组血气水平比对照组改善更明显(P<0.05);两组患者不良反应发生率无统计学差异(P>0.05)。结论复方异丙托溴铵联合布地奈德通过相互协同作用,加强抗炎、扩张支气管作用,从而提升疗效、改善患者血气水平及降低BNP水平。
Objective To compare the efficacy of aerosol inhalation of budesonide combined with compound ipratropium bromide in the treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with typeⅡrespiratory failureandits effects on blood gas indexes and plasma brain natriuretic peptide(BNP)level.Methods 120 cases of patients with COPD and typeⅡrespiratory failure in the hospital from January 2015 to January 2018 were selected and divided into two groups according to the random number table method,with 60 cases in each group.The two groups were given routine treatment,and control group was given aerosol inhalation of budesonide(2 mg/time,2 times/d)for 7 d on this basis,and observation group was given aerosol inhalation of compound ipratropium bromide(1.25 ml/time,2 times/d)for 7 don the basis of control group.The efficacy of the two groups was counted.The plasma BNP level and left ventricular ejection fraction(LVEF)were measured before and after treatment in the two groups.The lung function of the two groups was measuredbefore and after treatment,and the blood gas level before and after treatment were counted.The incidence rate of adverse reactions in the two groups was counted.Results After treatment,the symptom disappearance time in observation group was shorter than that in control group(P<0.05).After treatment,the cardiac function in observation group was significantly higher than that in control group,and the plasma BNP level was decreased more significantly than that in control group(P<0.05).After treatment,the lung function in observation group was improvedmoresignificantly than that in control group,(P<0.05).After treatment,the blood gas level inobservation group was improved more significantly than that in control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Compound ipratropium bromide combined with budesonide enhances anti-inflammatory and dilated bronchial effects through synergistic effects,thereby improving efficacy,promoting blood gas levels and reducing BNP level.
作者
白志峰
郭麒
刘沛
Bai Zhifeng;Guo Qi;Liu Pei(Department of General Internal Medicine,Anyang Third People's Hospital,Anyang 455000,China)
出处
《哈尔滨医药》
2019年第6期517-519,共3页
Harbin Medical Journal
关键词
布地奈德
复方异丙托溴氨
慢性阻塞性肺疾病
Ⅱ型呼吸衰竭
Budesonide
Compound ipratropium bromide
Chronic obstructive pulmonary disease
TypeⅡrespiratory failure